Clinical trial
Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or…
NCT00258232 · Barbara Ann Karmanos Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00258232 |
|---|---|
| Title | Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer |
| Official title | Phase II Study of Celecoxib, Capecitabine, and Irinotecan in Patients With Metastatic Colorectal Cancer |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, celecoxib, irinotecan hydrochloride |
| Start date | Jan 1, 2002 |
| Primary completion | Mar 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Nov 24, 2005 |
| Last update posted | Apr 8, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: